OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Net Common Stock Issuance

Last Annual Value

203.00K

3-Year CAGR

-16%

5-Year CAGR

-66%

10-Year CAGR

-42%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Net Common Stock Issuance

OKUR · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
203.00K
46.2%-72.6%N/A 
20.34M
8.0%-16.0%N/A
65.00K
-53.3%-77.0%N/A
101.65M
80.0%5.3%N/A
23.66M
53.4%-13.0%1.0%
87.78M
657.4%-5.5%N/A
29.25M
25.3%-3.7%6.2%
5.78M
-60.5%-33.1%N/A
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47